Ying Lin
Academic / Other · 1 registered clinical trial — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation Her-2 Negative Breast Cancer, HRR Gene Mutation | Phase 2 | 2022-05-06 |